Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Acquired by Barclays PLC

Barclays PLC increased its position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 276.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 273,085 shares of the biopharmaceutical company’s stock after purchasing an additional 200,482 shares during the quarter. Barclays PLC owned 0.13% of Akebia Therapeutics worth $360,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of AKBA. Bank of New York Mellon Corp grew its stake in Akebia Therapeutics by 3,122.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 604,551 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 585,789 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Akebia Therapeutics by 4,915.4% during the 2nd quarter. Rhumbline Advisers now owns 247,060 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 242,134 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Akebia Therapeutics by 7.2% during the 2nd quarter. Renaissance Technologies LLC now owns 3,914,800 shares of the biopharmaceutical company’s stock worth $3,993,000 after purchasing an additional 262,700 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Akebia Therapeutics by 40.7% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,221 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 9,037 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in Akebia Therapeutics during the 2nd quarter valued at $44,000. 33.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on AKBA shares. StockNews.com lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. HC Wainwright reissued a “buy” rating and set a $7.50 price objective on shares of Akebia Therapeutics in a research note on Tuesday, January 14th.

Akebia Therapeutics Price Performance

NASDAQ AKBA opened at $2.07 on Monday. Akebia Therapeutics, Inc. has a 12 month low of $0.80 and a 12 month high of $2.48. The company has a 50-day moving average of $1.91 and a 200-day moving average of $1.58. The company has a market cap of $451.63 million, a P/E ratio of -9.00 and a beta of 0.72.

Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The company had revenue of $37.43 million during the quarter, compared to analyst estimates of $45.66 million. During the same quarter in the prior year, the business earned ($0.08) earnings per share. As a group, equities research analysts anticipate that Akebia Therapeutics, Inc. will post -0.26 EPS for the current year.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.